Literature DB >> 23138855

Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?

Rik G J Marcellis1, Antoine F Lenssen, Geeuwke J de Vries, Robert P Baughman, Chris P van der Grinten, Johny A Verschakelen, Jolanda De Vries, Marjolein Drent.   

Abstract

BACKGROUND: Cardiopulmonary exercise testing (CPET) with blood gas analysis may be helpful when there is a discrepancy between clinical findings and physiologic tests at rest. The aim of this study was to examine the added value of CPET compared to the measurement of the diffusing capacity of the lung for carbon monoxide (DLCO) in detecting impaired pulmonary gas exchange in sarcoidosis patients.
METHODS: The clinical records of 160 (age = 41.3 ± 10.0 years; number of females = 63) sarcoidosis patients referred to the former MUMC ild care center were retrospectively reviewed. Patients performed a symptom-limited incremental exercise test with blood gas analysis on a bicycle ergometer. DLCO was measured by the single-breath method.
RESULTS: DLCO (mean = 83.2 ± 18.0 %) below 80 % of predicted was demonstrated by 38 % of the sarcoidosis patients in our sample. Of the patients with normal DLCO (n = 99, 61.9 %), the P(A-a)O(2) at maximal exercise [P(A-a)O(2)max] was moderately increased (>2.5 kPa) in 69.7 % and excessively increased (>4.7 kPa) in 18.2 %. Pulmonary gas exchange impairment (PGEI) was more obvious in patients with lower DLCO values. A DLCO value below 60 % of predicted indicated substantial gas exchange impairment. PaO(2) at rest, DLCO, and FVC as a percentage of predicted and radiographic staging predicted 40 % of the PGEI at maximal exercise.
CONCLUSION: A substantial number of the symptomatic sarcoidosis patients with normal DLCO appeared to have PGEI at maximal exercise, suggesting that normal DLCO at rest is an inappropriate predictor of abnormal pulmonary gas exchange during exercise. CPET appeared to offer added value in detecting impaired gas exchange during exercise in sarcoidosis patients with unexplained disabling symptoms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23138855     DOI: 10.1007/s00408-012-9432-6

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  45 in total

Review 1.  Pulmonary hypertension in sarcoidosis: a review.

Authors:  Tamera J Corte; Athol U Wells; Andrew G Nicholson; David M Hansell; Stephen J Wort
Journal:  Respirology       Date:  2011-01       Impact factor: 6.424

2.  Abnormal oxygen uptake responses to exercise in patients with mild pulmonary sarcoidosis.

Authors:  K E Sietsema; M Kraft; L Ginzton; O P Sharma
Journal:  Chest       Date:  1992-09       Impact factor: 9.410

Review 3.  Sarcoidosis.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki; Alvin S Teirstein
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

Review 4.  Six-minute walk test in managing and monitoring sarcoidosis patients.

Authors:  Robert P Baughman; Elyse E Lower
Journal:  Curr Opin Pulm Med       Date:  2007-09       Impact factor: 3.155

5.  Sarcoidosis: the value of exercise testing.

Authors:  A E Medinger; S Khouri; P K Rohatgi
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

6.  Clinical predictors of pulmonary hypertension in sarcoidosis.

Authors:  J M Bourbonnais; L Samavati
Journal:  Eur Respir J       Date:  2008-04-02       Impact factor: 16.671

7.  Exercise alveolar-arterial oxygen pressure difference in interstitial lung disease.

Authors:  C Risk; G R Epler; E A Gaensler
Journal:  Chest       Date:  1984-01       Impact factor: 9.410

8.  Clinical presentation of sarcoidosis in The Netherlands an epidemiological study.

Authors:  R M Wirnsberger; J de Vries; E F Wouters; M Drent
Journal:  Neth J Med       Date:  1998-08       Impact factor: 1.422

9.  Determinants of maximal inspiratory pressure. The Baltimore Longitudinal Study of Aging.

Authors:  R I Harik-Khan; R A Wise; J L Fozard
Journal:  Am J Respir Crit Care Med       Date:  1998-11       Impact factor: 21.405

10.  Cardiopulmonary exercise testing variables as predictors of long-term outcome in thoracic sarcoidosis.

Authors:  A J Lopes; S L S Menezes; C M Dias; J F Oliveira; M R M Mainenti; F S Guimarães
Journal:  Braz J Med Biol Res       Date:  2012-02-16       Impact factor: 2.590

View more
  7 in total

1.  Spirometry, cardiopulmonary exercise testing and the six-minute walk test results in sarcoidosis patients.

Authors:  Arda Kiani; Alireza Eslaminejad; Mohsen Shafeipour; Fatemeh Razavi; Seyyed Reza Seyyedi; Babak Sharif-Kashani; Habib Emami; Mehrdad Bakhshayesh-Karam; Atefeh Abedini
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

Review 2.  Morbidity and mortality in sarcoidosis.

Authors:  Alicia K Gerke
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

3.  Oxygen desaturation during a 6-minute walk test as a predictor of maximal exercise-induced gas exchange abnormalities in sarcoidosis.

Authors:  Cecile Chenivesse; Sarah Boulanger; Carole Langlois; Lidwine Wemeau-Stervinou; Thierry Perez; Benoit Wallaert
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

4.  Benefits of Physical Training in Sarcoidosis.

Authors:  Bert Strookappe; Jeff Swigris; Jolanda De Vries; Marjon Elfferich; Ton Knevel; Marjolein Drent
Journal:  Lung       Date:  2015-08-19       Impact factor: 2.584

5.  Exercise capacity, muscle strength, and fatigue in sarcoidosis: a follow-up study.

Authors:  Rik G J Marcellis; Antoine F Lenssen; Stephan Kleynen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2013-04-05       Impact factor: 2.584

6.  Reduction of exercise capacity in sarcoidosis in relation to disease severity.

Authors:  Anastasios Kallianos; Paul Zarogoulidis; Fotini Ampatzoglou; Georgia Trakada; Elias Gialafos; Georgia Pitsiou; Athanasia Pataka; Lemonia Veletza; Konstantinos Zarogoulidis; Wolfgang Hohenforst-Schmidt; Dimitris Petridis; Ioannis Kioumis; Aggeliki Rapti
Journal:  Patient Prefer Adherence       Date:  2015-08-18       Impact factor: 2.711

Review 7.  Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis.

Authors:  Pascal Sève; Yves Pacheco; François Durupt; Yvan Jamilloux; Mathieu Gerfaud-Valentin; Sylvie Isaac; Loïc Boussel; Alain Calender; Géraldine Androdias; Dominique Valeyre; Thomas El Jammal
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.